RNA interference mediated silencing of α-synuclein in MN9D cells and its effects on cell viability

Neuroscience Bulletin

Volumn 24, Issue 2, 2008, Pages 96-104

  Liu, Dong Mei ^a   Jin, Ling ^a   Wang, Hao ^b   Zhao, Huan Ying ^a   Zhao, Chun Li ^a   Yang, Hui ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Synuclein; Parkinson's disease; RNA interference

Indexed keywords

ALPHA SYNUCLEIN; DOUBLE STRANDED RNA; MESSENGER RNA; NUCLEOTIDE; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; EMBRYO; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA SEQUENCE; SILENCER GENE; STAINING; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; ANIMALS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GENE SILENCING; GENETIC VECTORS; HYBRIDOMAS; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURONS; OLIGONUCLEOTIDES; PARKINSON DISEASE; PLASMIDS; RNA INTERFERENCE; RNA, DOUBLE-STRANDED; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 44349127816     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12264-008-0096-4     Document Type: Article

References (51)

1. Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, Giusti P. Alpha-synuclein and Parkinson's disease. FASEB J 2004, 18: 617-626.
2. Martin FL, Williamson SJ, Paleologou KE, Allsop D, El-Agnaf OM. Alpha-synuclein and the pathogenesis of Parkinson's disease. Protein Pept Lett 2004, 11: 229-237.
3. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997, 276: 2045-2047.
4. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998, 18: 106-108.
5. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, et al. The E46K mutation in α-synuclein increases amyloid fibril formation. J Biol Chem 2005, 280: 7800-7807.
6. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. α-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
7. Chan P, Tanner CM, Jiang X, Langston JW. Failure to find the α-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology 1998, 50: 513-514.
8. Chan P, Jiang X, Forno LS, Di Monte DA, Tanner CM, Langston JW. Absence of mutations in the coding region of the α-synuclein gene in pathologically proven Parkinson's disease. Neurology 1998, 50: 1136-1137.
9. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. α-synuclein in Lewy bodies. Nature 1997, 388: 839-840.
10. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998, 95: 6469-6473.
11. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998, 152: 879-884.
12. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E. Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders. Am J Pathol 1998, 152: 367-372.
13. Trojanowski JQ, Lee VM. Aggregation of neurofilament and α-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 1998, 55: 151-152.
14. Arima K, U'eda K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H, et al. Immunoelectron microscopic demonstration of NACP/α-synuclein epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res 1998, 808: 93-100.
15. Rajagopalan S, Andersen JK. Alpha-synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease? Mech Ageing Dev 2001, 122: 1499-1510.
16. Tabner BJ, Turnbull S, El-Agnaf OM, Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 2002, 32: 1076-1083.
17. Lotharius J, Brundin P. Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 2002, 11: 2395-2407.
18. Lykkebo S, Jensen PH. Alpha-synuclein and presynaptic function: implications for Parkinson's disease. Neuromolecular Med 2002, 2: 115-129.
19. Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat Rev Neurosci 2002, 3: 932-942.
20. Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, et al. Interactions among α-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 2004, 23: 23-34.
21. Perez RG, Hastings TG. Could a loss of α-synuclein function put dopaminergic neurons at risk? J Neurochem 2004, 89: 1318-1324.
22. Yu S, U'eda K, Chan P. Alpha-synuclein and dopamine metabolism. Mol Neurobiol 2005, 31: 243-254.
23. Abeliovich A, Schmitz Y, Fariñas I, Choi-Lundberg D, Ho WH, Castillo PE, et al. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25: 239-252.
24. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. A role for α-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002, 22: 3090-3099.
25. Wersinger C, Sidhu A. Attenuation of dopamine transporter activity by α-synuclein. Neurosci Lett 2003, 340: 189-192.
26. Baptista MJ, O'Farrell C, Daya S, Ahmad R, Miller DW, Hardy J, et al. Co-ordinate transcriptional regulation of dopamine synthesis genes by α-synuclein in human neuroblastoma cell lines. J Neurochem 2003, 85: 957-968.
27. Sidhu A, Wersinger C, Vernier P. Does α-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J 2004, 18: 637-647.
28. Sidhu A, Wersinger C, Vernier P. Alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett 2004, 565: 1-5.
29. Yu S, Zuo X, Li Y, Zhang C, Zhou M, Zhang YA, et al. Inhibition of tyrosine hydroxylase expression in α-synuclein-transfected dopaminergic neuronal cells. Neurosci Lett 2004, 367: 34-39.
30. Yavich L, Tanila H, Vepsäläinen S, Jäkälä P. Role of α-synuclein in presynaptic dopamine recruitment. J Neurosci 2004, 24: 11165-11170.
31. Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL. Substratemediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of α-synuclein. J Neurochem 2006, 96: 950-959.
32. Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, et al. α-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 1999, 19: 5782-5791.
33. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, et al. Ubiquitination of a newform of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001, 293: 263-269.
34. Ghee M, Fournier A, Mallet J. Rat α-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J Neurochem 2000, 75: 2221-2224.
35. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R. α-synuclein binds to Tau and stimulates the protein kinase Acatalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem 1999, 274: 25481-25489.
36. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. β-synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 2001, 32: 213-223.
37. Yoshimoto M, Iwai A, Kang D, Otero DA, Xia Y, Saitoh T. NACP, the precursor protein of the non-amyloid β/A4 protein (A β) component of Alzheimer disease amyloid, binds A β and stimulates A β aggregation. Proc Natl Acad Sci USA 1995, 92: 9141-9145.
38. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391: 806-811.
39. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev 2001, 15: 188-200.
40. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003, 4: 457-467.
41. Brummelkamp TR, Bernards R, Agami RA. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296: 550-553.
42. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002, 16: 948-958.
43. Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, Bohn MC. Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 2006, 198: 382-390.
44. 2 in a human neuroblastoma divided cell line transfected with α-synuclein and its familial Parkinson's disease-linked mutants. Neurosci Lett 2003, 342: 124-128.
45. Oshiumi H, Begum NA, Matsumoto M, Seya T. RNA interference for mammalian cells. Nippon Yakurigaku Zasshi 2002, 120: 91-95.
46. Perez RG, Hastings TG. Could a loss of α-synuclein function put dopaminergic neurons at risk? J Neurochem 2004, 89: 1318-1324.
47. Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999, 55: 659-665.
48. LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 1999, 19: 1484-1491.
49. Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 1999, 73: 1127-1137.
50. 2 and hydroxyl radicals but not lutathione-protein-mixed disulfides. J Neurochem 2002, 82: 66-74.
51. Ben-Shachar D, Zuk R, Gazawi H, Ljubuncic P. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem Pharmacol 2004, 67: 1965-1974.